Damora Therapeutics, Inc. (DMRA): Shareholders' Equity
$240.38M
As of 2025-12-31
$516.06M
As of 2026-06-30
+57.3%
3-year compound annual growth
+7.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $240.38M | n/m | 2026-03-19, Balance as of period end |
| 2024-12-31 | $15.83M | -51.0% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $32.33M | -47.6% | 2025-03-19, Balance as of period end |
| 2022-12-31 | $61.75M | -47.3% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $117.22M | -29.2% | 2023-03-09, Balance as of period end |
| 2020-12-31 | $165.49M | n/m | 2022-02-17, Balance as of period end |
| 2019-12-31 | -$71.15M | n/a | 2021-03-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Damora Therapeutics, Inc. (DMRA) | 2025-12-31 | $240.38M | n/m |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $161.55M | +0.3% |
| Phathom Pharmaceuticals, Inc. (PHAT) | 2025-12-31 | -$438.17M | n/m |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $206.75M | +519.8% |
| Macrogenics Inc (MGNX) | 2025-12-31 | $55.59M | -52.1% |
| Heron Therapeutics, Inc. (HRTX) | 2025-12-31 | $14.33M | n/m |
| Perspective Therapeutics, Inc. (CATX) | 2025-12-31 | $207.03M | -28.8% |
| Savara Inc (SVRA) | 2025-12-31 | $203.13M | +18.5% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $213.99M | -11.2% |
Compare DMRA, NATR, PHAT, ASMB side by side · Screen every company in Pharmaceutical Preparations ↗